EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis

Wenjun Ji, Kai Qing, Jiayi Ren, Kai Xue iD, Jie Fang iD, Shishuang Wu iD

Journal of Cellular and Molecular Medicine · 2026

DOI: 10.1111/jcmm.71173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Wenjun Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Nitriles, Blood-Brain Barrier, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Tibet Autonomous Region, Natural Science Foundation of Shigatse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haemophagocytic lymphohistiocytosis (HLH), complicated by the involvement of the central nervous system (CNS), contributes to high morbidity and mortality with rapid development and violent cytokine storms in the CNS. Consequently, intrathecal dexamethasone and methotrexate must be administered in a timely manner to treat CNS inflammation. No effective pharmacotherapy targeting cytokine pathways is available to suppress cytokine storms that occur in the CNS. Ruxolitinib, a JAK1/2 inhibitor, has been recommended for the treatment of HLH by multiple guidelines. Conventional studies have reported that ruxolitinib cannot penetrate the blood brain barrier (BBB), thereby impeding the implementation of numerous therapies. Our team previously identified the efficacy of ruxolitinib in patients with CNS‐HLH. Ten patients with secondary HLH (two with CNS involvement and eight without) received ruxolitinib, and BBB permeability was evaluated. Ruxolitinib exhibited BBB penetrability, ranging from 5.31% to 18.08%, suggesting its promising potential in CNS therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticNitrilesBlood-Brain BarrierPyrazolesCytokine Release SyndromeHumansPyrimidinesFemaleMaleChild, PreschoolCytokinesChild

Stichwörter der Autor:innen

BBB permeabilityCNS‐HLHruxolitinib

Substanzen

ruxolitinibPyrimidinesNitrilesPyrazolesCytokines

Autor:innen und Institutionen

  • Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,…

ORCID-Profile: Kai Xue, Jie Fang, Shishuang Wu

Förderung

  • Natural Science Foundation of Tibet Autonomous Region
  • Natural Science Foundation of Shigatse

Zitieren

APA

Ji, W., Qing, K., Ren, J., Xue, K., Fang, J., & Wu, S. (2026). Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71173

Vancouver

Ji W, Qing K, Ren J, Xue K, Fang J, Wu S. Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71173

BibTeX
@article{Ji2026,
  author = {Ji, Wenjun and Qing, Kai and Ren, Jiayi and Xue, Kai and Fang, Jie and Wu, Shishuang},
  title = {Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  doi = {10.1111/jcmm.71173}
}
Kostenlos starten →